871836-51-0

Basic information

• Product Name: HDH-PHARMA 26173
• Synonyms: 4-CHLORO-1H-PYRAZOLO[4,3-C]PYRIDINE;HDH-PHARMA 26173;1H-Pyrazolo[4,3-c]pyridine,4-chloro-;4-chloro-1H-pyrazolo[4,3-c]pyridin-6-aMine;4-chloro-1H-pyrazolo[4;4-Chloro-1H-pyrazolo[4,3-...;EOS-61542
• CAS NO: 871836-51-0
• Molecular Formula: C₆H₄ClN₃
• Molecular Weight: 153.572
• EINECS: 937-467-3
• Product Categories: Heterocycle-Pyridine series
• Mol File: 871836-51-0.mol
• Article Data: 11

Chemical Properties

• Boiling Point: 357.485 °C at 760 mmHg
• Flash Point: 201.244 °C
• Appearance: /
• Density: 1.531
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.72
• Storage Temp.: under inert gas (nitrogen or Argon) at 2–8 °C
• PKA: 10.46±0.40(Predicted)
• CAS DataBase Reference: HDH-PHARMA 26173(CAS DataBase Reference)
• NIST Chemistry Reference: HDH-PHARMA 26173(871836-51-0)
• EPA Substance Registry System: HDH-PHARMA 26173(871836-51-0)

Safety Data

• Hazardous Substances Data: 871836-51-0(Hazardous Substances Data)

Usage

Uses

4-Chloro-1H-pyrazolo[4,3-c]pyridine is used to prepare gp120-?CD4 inhibitors.

InChI:InChI=1/C6H4ClN3/c7-6-4-3-9-10-5(4)1-2-8-6/h1-3H,(H,9,10)

Upstream product

• 153034-86-7 2-chloro-4-iodopyridine 
• 79055-64-4 2-chloro-4-amino-3-methylpyridine 
• 153034-90-3 2-Chloro-4-iodo-3-pyridinecarboxaldehyde 
• 26452-80-2 2,4-dichloropyridine 
• 134031-24-6 2,4-dichloro-3-pyridine Carboxaldehyde 
• 871836-50-9 1H-pyrazolo[4,3-c]pyridine N-oxide 

Downstream Products

• 1160360-05-3 4-chloro-1-(4-fluorobenzyl)-1H-pyrazolo[4,3-c]pyridine 
• 1160360-06-4 C₁₃H₉ClFN₃ 
• 1246349-97-2 4-chloro-3-iodo-1-(4-methoxybenzyl)-1H-pyrazolo[4,3-c]pyridine 
• 1246349-98-3 cyclohexyl-[3-iodo-1-(4-methoxy-benzyl)-1H-pyrazolo[4,3-c]pyridin-4-yl]-amine 
• 1246348-26-4 4-[2-(4-cyclohexylamino-1H-pyrazolo[4,3-c]pyridin-3-yl)-ethyl]-benzoic acid methyl ester 
• 1246350-26-4 4-[2-(4-cyclohexylamino-1H-pyrazolo[4,3-c]pyridin-3-yl)-ethyl]-benzoic acid 
• 1378037-55-8 N-(2-(2,6-dichlorophenyl)-2H-pyrazolo[4,3-c]pyridin-4-yl)cyclopropanecarboxamide 
• 1378037-56-9 [2-(2,6-dichlorophenyl)-2H-pyrazolo[4,3-c]pyridine-4-yl]-(2,6-dimethylpyrimidin-4-yl)amine 
• 1378038-47-1 1-{6-[2-(2,6-dichlorophenyl)-2H-pyrazolo[4,3-c]pyridin-4-ylamino]-pyrimidin-4-yl}-ethanol 
• 1378038-48-2 (6-cyclopropylpyrimidin-4-yl)-[2-(2,6-dichlorophenyl)-2H-pyrazolo[4,3-c]pyridin4-yl]-amine 
• 1378037-57-0 6-[2-(2,6-dichlorophenyl)-2H-pyrazolo[4,3-c]pyridin-4-ylamino]nicotinonitrile 
• 41372-94-5 4-chloro-2-methyl-2H-pyrazolo[4,3-c]pyridine 
• 41372-97-8 1-benzyl-4-chloro-1H-pyrazolo[4,3-c]pyridine 

Relevant articles and documents

Pyrazolopyridine compound and preparation method thereof

The embodiment of the invention discloses a pyrazolopyridine compound and a preparation method thereof. The preparation method includes the steps of: taking 2-chloro-4-amino-3-methylpyridine as the raw materials to prepare a compound shown as formula (III). The preparation method takes 2-chloro-4-amino-3-methylpyridine as the raw materials to prepare 4-chloro-1H-pyrazolo[4, 3-c]pyridine, has the advantages of cheap and easily available raw materials, high reaction activity, mild reaction conditions, simple separation and purification method, high product purity, etc., and can be well applied to industrial production.

Identification of an imidazopyridine scaffold to generate potent and selective TYK2 inhibitors that demonstrate activity in an in vivo psoriasis model

Herein we report identification of an imidazopyridine class of potent and selective TYK2 inhibitors, exemplified by prototype 6, through constraint of the rotatable amide bond connecting the pyridine and aryl rings of compound 1. Further optimization led to generation of compound 30 that potently inhibits the TYK2 enzyme and the IL-23 pathway in cells, exhibits selectivity against cellular JAK2 activity, and has good pharmacokinetic properties. In mice, compound 30 demonstrated dose-dependent reduction of IL-17 production in a PK/PD model as well as in an imiquimod-induced psoriasis model. In this efficacy model, the IL-17 decrease was accompanied by a reduction of ear thickness indicating the potential of TYK2 inhibition as a therapeutic approach for psoriasis patients.

HETEROCYCLIC COMPOUND

The present invention provides a compound having a superior JAK inhibitory action, which is useful as an agent for the prophylaxis or treatment of autoimmune diseases (rheumatoid arthritis, psoriasis, inflammatory bowel disease, Sjogren's syndrome, Behcet's disease, multiple sclerosis, systemic lupus erythematosus, etc.), cancer (leukemia, uterine leiomyosarcoma, prostate cancer, multiple myeloma, cachexia, myelofibrosis, etc.) and the like, or a salt thereof. The present invention relates to a compound represented by the formula wherein each symbol is as defined in the specification, or a salt thereof.